Regeneron Pharmaceuticals Sees Reduced Stake from Capital International Inc. CA

Institutional investor decreases position in biotech company by nearly 50%

Mar. 11, 2026 at 8:24am

Got story updates? Submit your updates here. ›

Capital International Inc. CA, a major institutional investor, decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 47.3% in the 3rd quarter, according to a recent SEC filing. The firm now owns 37,370 shares of the biopharmaceutical company's stock, down from 70,855 shares previously.

Why it matters

Regeneron Pharmaceuticals is a prominent biotech company known for its innovative drug discovery technologies and pipeline of biologic therapies. Changes in institutional ownership can signal shifts in investor sentiment and market expectations around the company's performance and future prospects.

The details

According to the 13F filing, Capital International Inc. CA sold 33,485 shares of Regeneron Pharmaceuticals during the third quarter. The firm's remaining stake in the company is now valued at $21,012,000. Several other large investors have also bought and sold Regeneron shares in recent quarters, reflecting the stock's volatility and the broader trends in the biotech sector.

  • Capital International Inc. CA decreased its Regeneron Pharmaceuticals position in the 3rd quarter of 2026.

The players

Capital International Inc. CA

A major institutional investor that has decreased its stake in Regeneron Pharmaceuticals by nearly 50%.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Capital International Inc. CA's Regeneron Pharmaceuticals position reflects broader volatility in the biotech sector and changing investor sentiment around the company's prospects. However, Regeneron remains a prominent player in the industry known for its drug discovery capabilities.